Akebia discloses preliminary unaudited Auryxia net product revenue for FY2023 in JPM conference presentation

Akebia Therapeutics, Inc.

Presentation at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024 includes preliminary Auryxia revenue.
Preliminary unaudited net product revenue for Auryxia for fiscal year ended Dec 31, 2023; exact figures not in filing text.
Investor and analyst meetings coincide with the J.P. Morgan Healthcare Conference starting Jan 8, 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Akebia Therapeutics, Inc. reported preliminary financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: preliminary results

Exact text from the filing

John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at the 42 nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 at 11:15 a.m. PST, which includes preliminary unaudited net product revenue for Auryxia® cumulative and for the fiscal year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.